NVRO Stock Recent News
NVRO LATEST HEADLINES
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.
Nevro Corp. (NYSE:NVRO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group LLC Kevin Thornal - President and CEO Rod MacLeod - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Group Simran Kaur - Piper Sandler Nathan Treybeck - Wells Fargo Allen Gong - JPMorgan Brandon Vazquez - William Blair Brad Bowers - Mizuho Securities David Turkaly - JMP Securities Operator Ladies and gentlemen, good afternoon. My name is Abby, and I will be your conference operator today.
Nevro (NVRO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.71 per share a year ago.
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts could bring significant FCF growth and stock price appreciation.
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript.
Nevro (NVRO) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.98 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Today Nevro announced the appointment of a new CEO/president along with its preliminary 2023 Q1 financial results. With a possible recession looming, investors are exiting the cash-flow-negative medtech today.